Virus Cases in Hubei Jump, Maintain Optionality

Equities 4 minutes to read

Eleanor Creagh

Australian Market Strategist

Summary:  Hubei province has revised its method of counting novel coronavirus pneumonia. Have markets jumped the gun with respect to pricing the impact of this virus outbreak?


China’s Hubei province has revised its method of counting novel coronavirus pneumonia (COVID-19) infections, altering the diagnostic criteria, which has seen a huge jump in confirmed cases. Today Hubei Province reported 14,840 new confirmed cases, including 13,332 clinically diagnosed cases of COVID-19, almost 10 times compared to a day earlier. Have markets jumped the gun with respect to pricing the impact of this virus outbreak?

New cases in Hubei have jumped, why? Officials are now giving doctors greater discretion to clinically diagnose patients. A suspected case will be clinically diagnosed as long as the patient shows pulmonary lesions following a CT scan, even if they have not been given a nucleic acid test that detects the virus’ signature. This move is aimed at controlling the spread and providing a greater level of care to potentially infected patients, but it has also added a vast number of people to the official count. A detailed analysis of what this step means should be left for the medical professionals and epidemiologists, but one thing is for sure, there is a huge question mark over the reliability of official data from China. Health experts continue to question the timeliness and accuracy of the data. This means that within any forecast outcomes should be embedded a large degree of variability. The situation remains very fluid, however markets still don’t appear to be overly worried whilst the outbreak is relatively contained within China. This sentiment is somewhat complacent given China’s contribution to global growth and importance within intertwined global supply chains generating the potential for production bottle necks – particularly in tech and autos sectors, notwithstanding lost output as it relates to goods and services trade.

Shutdowns in China look to be more protracted than original expectations, many factories have not resumed production and cities are still on lockdown as measures are taken to limit the virus spread. This is particularly concerning not just in terms of the direct effects but also the capacity for non-linear secondary effects to cascade as shutdowns become more protracted, this is not priced into equities. However, upside momentum is strong, particularly for US equity indices, and investors are heeding the impending monetary and fiscal stimulus and influx of liquidity from China. Given the complete lack of reliable data it is prudent to maintain optionality at this stage, in order to protect against the potential for economic disruptions to drag well into Q2.

Restoring production back to full capacity will not be an easy task and activity will resume in dribs and drabs. Real-time data like property sales, coal consumption and road congestion displays a worrying picture for those expecting a quick return to capacity. The ultimate impact remains highly variable and the jury is still out as it relates to more protracted activity disruptions, so whilst markets seem resilient at present, that could change. A far slower return to normal that would have deeper and more pronounced effects cannot be ruled out until activity has started to normalise. This is not the case at present.

At this stage the hit to the US economy should be manageable, but China has been hit hard. This disruption will dent global growth. Forecasting that is dependent upon the 2003 SARs outbreak is likely not a good replica – China is a far larger component of the global economy than in 200, and consumer spending also makes up a bigger share of China's economy.

The commitment from China to maintain official growth targets using a range of stimulus measures is lending a degree of confidence to investors at this stage, along with notion FED and other central banks are ready to step in on any growth wobbles. In reality, China GDP in Q1 is likely to be close to 0 and potentially negative depending on how protracted the shutdown is as we wrote earlier this week. Investors are banking on ample liquidity and celebrating in advance looser financial conditions. China will be stepping on the stimulus pedal, along with providing heightened state support to encourage consumption and production. Another key focus is limiting job losses, employment remains key for social stability. But policymakers must tread a very fine line as years of credit driven growth, state intervention and industrial over capacity leaves a multitude of financial stability concerns. Tackling the sharp hit to growth must be counterbalanced against adding to vulnerabilities already present within China’s financial system.

 

Disclaimer

Saxo Capital Markets (Australia) Pty Ltd prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Combined Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Pty Ltd ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide and Product Disclosure Statement to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as CFDs and Margin FX products may result in your losses surpassing your initial deposits. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.
Please click here to view our full disclaimer.